Clinical Trial: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Condition: Alzheimer Disease
Study Type: INTERVENTIONAL
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease
Brief Summary:
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap compared with placebo in participants with mild to moderate Alzheimer's disease.Study details include:The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home.The study duration will be 4-5 months.There will be 4 in-clinic visits and 1 phone call.
Read more